H2A.Z.2 is highly expressed in metastatic melanoma, correlates with decreased patient survival, and promotes and maintains BRD2, E2F1, and histone acetylation levels to drive melanoma proliferation, which suggests a potential epigenetic therapeutic strategy to improve drug sensitivity in malignant melanoma. This evidence concerns the gene E2F1 and melanoma.